More than 300 mutations in PSEN1 have been catalogued, but none are quite like the one Bart De Strooper and colleagues at the Flanders Institute for Biotechnology in Leuven, Belgium, reported on ...
Contact Information Subodh Verma, M.D., Ph.D., FRCSC, FAHA, FCAHS Toronto, CanadaProfessional Information ProfessorUniversity of Toronto ...
The APOE4 allele heightens the risk of Alzheimer’s disease in several ways. Here’s a new one: It may deprive neurons of a crucial fuel. In the October 16 Nature Metabolism, scientists led by Thomas ...
Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...
On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...
Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...
At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
West Virginia University B.S. 08/2000 Exercise Physiology West Virginia University M.S 08/2001 Clinical Exercise Physiology West Virginia University: School of Medicine Ph.D. 05/2008 Biomedical ...
This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback